TSO3 to Present at Upcoming Investor Conferences

QUÉBEC CITY, Aug. 4, 2016 /CNW Telbec/ - TSO₃ Inc. (TSX: TOS) ("TSO₃" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, has been invited to present at two financial conferences being held in August 2016.

Canaccord Genuity 36th Annual Growth Conference

Presentation: Thursday, August 11, 2016 at 2:30 p.m. EDT
Where: Intercontinental Boston Hotel in Boston, Massachusetts
Webcast: http://wsw.com/webcast/canaccord23/tos

Wedbush PacGrow Healthcare Conference

Presentation: Tuesday, August 16, 2016 at 9:45 a.m. EDT
Where: Le Parker Meridien in New York, New York

Management will discuss the Company's business, recently received Food and Drug Administration clearance for extended claims, commercial rollout and future planned enhancements for its STERIZONE^® VP4 Sterilizer.

Additionally, management will be available for one-on-one meetings with attendees during each conference. For more information about the conferences or to schedule a one-on-one meeting with TSO₃ management, please contact your respective conference representative or call the Company's investor relations team at 949-574-3860.

About TSO₃

Founded in 1998, TSO₃'s activities encompass the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. It also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.

TSO₃ recently announced that it had received U.S. clearance for extended claims relating to the terminal sterilization of multi-channel flexible endoscopes. The FDA clearance of additional claims represents an entirely new level of patient protection against ineffective device reprocessing resulting from the use of less robust systems like high-level disinfection, particularly for video colonoscopes and gastroscopes.

For more information about TSO₃, visit the Company's web site at www.tso3.com.                   

The statements in this release and oral statements made by representatives of TSO₃ relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of TSO₃'s sales, business or operations) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, the ability of the Company to obtain the required regulatory clearance to market its products on a worldwide basis;general business and economic conditions, the condition of the financial markets, the ability of TSO₃ to obtain financing on favourable terms and other risks and uncertainties. 

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful.

SOURCE TSO3 Inc.

Company Contacts: TSO3 Inc., R.M. (Ric) Rumble, President and CEO, Tel: [phone], Email: [email protected]; TSO3 Inc., Glen Kayll, CFO, Tel: [phone], Email: [email protected]; Investor Relations: Liolios Group, Inc., Ron Both, Tel: [phone], [email protected]; Renmark Financial Communications Inc., Barry Mire, Tel: [phone] or 514 939-3989, [email protected]